NcXHF

CARROLL, RAETZ, AND MEYER
markers and interventions are defıned at the outset. The National
Cancer Institute (NCI) MATCH prospective clinical trial
will open for patients age 18 or older in which standard therapy
has failed and who are willing to undergo a rebiopsy. 44 Analysis
of approximately 200 genes that have been selected for alignment
with a targeted agent will be performed in one of four
Clinical Laboratory Improvement Amendment-certifıed laboratories.
The trial will use FDA-approved drugs outside of their
indication as well as agents not yet approved but that have
shown activity in a given tumor type. The NCI MATCH study
will be open to all four adult cooperative groups. NCI is now
planning a Pediatric MATCH study with COG, thus, paving the
way for precision medicine for all COG members.
SUMMARY AND CONCLUSIONS
Next-generation genomic analysis of pediatric tumors has
yielded profound insights into the origins of childhood cancers
and has shed light on biologic pathways that drive tumorigenesis
and drug resistance. Integration of new agents
on a backbone of traditional therapy is being pursued in
many tumor types, and there is great anticipation that such
approaches will lead to improved outcomes. The integration
of NGS into therapeutic decision making for individual patients
poses many technical, fınancial, and biologic challenges.
It may be anticipated that such hurdles will be
overcome through careful application of precision medicine
in the context of rigorous clinical trials.
Disclosures of Potential Conflicts of Interest
The author(s) indicated no potential conflicts of interest.
References
1. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival
with imatinib in Philadelphia chromosome-positive acute lymphoblastic
leukemia: a children’s oncology group study. J Clin Oncol.
2009;27:5175-5181.
2. Garraway LA. Genomics-driven oncology: framework for an emerging
paradigm. J Clin Oncol. 2013;31:1806-1814.
3. Janeway KA, Place AE, Kieran MW, et al. Future of clinical genomics in
pediatric oncology. J Clin Oncol. 2013;31:1893-1903.
4. Sheridan C. Illumina claims $1,000 genome win. Nat Biotechnol. 2014;
32:115.
5. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome
landscapes. Science. 2013;339:1546-1558.
6. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifıes
genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45:
602-612.
7. Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies
highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122:
2983-2988.
8. Jones C, Baker SJ. Unique genetic and epigenetic mechanisms driving
paediatric diffuse high-grade glioma. Nat Rev Cancer. 2014;14.
9. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:
2202-2211.
10. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of highrisk
neuroblastoma. Nat Genet. 2013;45:279-284.
11. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma
by BET bromodomain inhibition. Cancer Discov. 2013;3:308-323.
12. Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses
super-enhancer-linked oncogenic transcription in MYCNdriven
cancer. Cell. 2014;159:1126-1139.
13. Brohl AS, Solomon DA, Chang W, et al. The genomic landscape of the
Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.
PLoS Genet. 2014;10:e1004475.
14. Tirode F, Surdez D, Ma X, et al. Genomic landscape of Ewing sarcoma
defınes an aggressive subtype with co-association of STAG2 and TP53
mutations. Cancer Discov. 2014;4:1342-1353.
15. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis
of rhabdomyosarcoma reveals a landscape of alterations affecting a
common genetic axis in fusion-positive and fusion-negative tumors.
Cancer Discov. 2014;4:216-231.
16. Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches
highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Proc Natl Acad SciUSA.2014;111:E5564-E5573.
17. Meyer JA, Wang J, Hogan LE, et al. Relapse-specifıc mutations in
NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013;45:
290-294.
18. Jones CL, Bhatla T, Blum R, et al. Loss of TBL1XR1 disrupts glucocorticoid
receptor recruitment to chromatin and results in glucocorticoid
resistance in a B-lymphoblastic leukemia model. J Biol Chem. 2014;289:
20502-20515.
19. Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed
childhood acute lymphoblastic leukemia reveals therapeutic
strategies. Blood. 2011;118:5218-5226.
20. Dandekar S, Romanos-Sirakis E, Pais F, et al. Wnt inhibition leads to
improved chemosensitivity in paediatric acute lymphoblastic leukaemia.
Br J Haematol. 2014;167:87-99.
21. Jones CL, Gearheart CM, Fosmire S, et al. MAPK signaling cascades
mediate distinct glucocorticoid resistance mechanisms in pediatric
B-precursor ALL. Paper presented at: American Society of Hematology
Annual Meeting and Exposition; December 2014; San Francisco, CA.
22. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for
paediatric patients with refractory solid tumours or anaplastic large-cell
lymphoma: a Children’s Oncology Group phase 1 consortium study.
Lancet Oncol. 2013;14:472-480.
23. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for
treatment of children and adolescents with Philadelphia-chromosomepositive
acute lymphoblastic leukaemia (EsPhALL): a randomised,
open-label, intergroup study. Lancet Oncol. 2012;13:936-945.
24. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib
in pediatric Philadelphia chromosome-positive acute lymphoblastic
leukemia: Children’s Oncology Group study AALL0031. Leukemia.
2014;28:1467-1471.
25. Slayton WB SK, Jones T, et al. Continuous dose dasatinib is safe and
feasible in combination with intensive chemotherapy in pediatric Philadelphia
chromosome positive acute lymphoblastic leukemia (Ph
e606
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook